Renal papillary necrosis following emergency department treatment of migraine.
New medications have lessened the need for narcotic medications in the acute treatment of migraine. Some of these new medications include parenteral dihydroergotamine (DHE), sumatriptan, and ketorolac. Treatment failures still occur, though, and some cases necessitate adding a second agent to one that has been ineffective. We report a case of a 46-year-old man who suffered renal papillary necrosis 12 days after receiving parenteral DHE, sumatriptan, and ketorolac for treatment of a severe migraine headache. There were no signs of an adverse drug reaction at the time of his emergency department visit. The case illustrates a potential hazard of this combination in the acute treatment of migraine.
Witting
M D
MD
Department of Surgery, University of Maryland Medical Center, Baltimore 21201, USA.
D018712:Analgesics, Non-Narcotic / Q000009:adverse effects*; D004087:Dihydroergotamine / Q000009:adverse effects*; D004347:Drug Interactions; D004630:Emergencies; D006801:Humans; D020910:Ketorolac; D007681:Kidney Papillary Necrosis / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D018170:Sumatriptan / Q000009:adverse effects*; D014046:Tolmetin / Q000009:adverse effects / Q000031:analogs & derivatives*; D014662:Vasoconstrictor Agents / Q000009:adverse effects*
D018712:Analgesics, Non-Narcotic; D014662:Vasoconstrictor Agents; D004087:Dihydroergotamine; D018170:Sumatriptan; D014046:Tolmetin; D020910:Ketorolac